Table 1.
Characteristics of included studies
| ID | Author | Year | Area | n | Episodes of sepsis | Infected/noninfected | Diagnosis standard | Type of sepsis | Infants | nCD64 analysis | Analysis cut-off | TP | FP | FN | TN |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Bhandari | 2008 [7] | USA | 163 | 293 | 128/165 | Clinical or proven | b | Preterm | FCM | 2.30* | 90 | 63 | 38 | 102 |
| 2 | Dilli | 2010 [21] | Turkey | 109 | 109 | 35/74 | Clinical or proven | c | Preterm + term | FCM | 4.39* | 31 | 11 | 4 | 63 |
| 3 | Genel | 2012 [22] | Turkey | 119 | 119 | 49/70 | Clinical or proven | c | Preterm + term | FCM | 3.05 MFI | 40 | 16 | 9 | 54 |
| 4 | Groselj-Grenc | 2009 [23] | Slovenia | 46 | 46 | 17/29 | Clinical or proven | c | Preterm + term | FCM | 1.86* | 13 | 6 | 4 | 23 |
| 5 | Lam | 2011 [24] | China | 310 | 310 | 136/174 | Clinical or proven | a | Preterm + term | FCM | 6010 $ | 107 | 37 | 29 | 137 |
| 6 | Motta | 2014 [25] | Italy | 129 | 129 | 48/81 | Clinical or proven | a | Preterm | FCM | 2.4* | 31 | 12 | 17 | 69 |
| 7 | Ng | 2004 [26] | China | 359 | 359 | 115/244 | Clinical or proven | a | Term | FCM | 5500 $ | 93 | 46 | 22 | 198 |
| 8 | Ng | 2006 [27] | China | 298 | 298 | 93/205 | Clinical or proven | a | Term | FCM | 6136 $ | 73 | 20 | 20 | 185 |
| 9 | Zeitoun | 2010 [30] | USA | 98 | 98 | 49/49 | Clinical or proven | c | Preterm + term | FCM | 2.6* | 45 | 14 | 4 | 35 |
| 10 | Du | 2014 [11] | China | 158 | 158 | 88/70 | Clinical | a | Preterm | FCM | 1010 $ | 72 | 21 | 16 | 49 |
| 11 | Elawady | 2014 [12] | Egypt | 50 | 50 | 25/25 | Clinical | b | Preterm + term | FCM | 46.0 | 24 | 0 | 1 | 24 |
| 12 | Layseca-Espinosa | 2002 [8] | Mexico | 29 | 29 | 14/15 | Clinical | c | Preterm + term | FCM | # | 3 | 0 | 11 | 15 |
| 13 | Streimish(a) | 2014 [29] | USA | 684 | 1156 | 207/416 | Clinical | a | Preterm | FCM | 1.63 | 139 | 137 | 68 | 279 |
| 14 | Streimish(b) | 2014 [29] | USA | 204/329 | Clinical | b | Preterm | FCM | 2.19 | 159 | 135 | 45 | 194 | ||
| 15 | Choo | 2012 [20] | Korea | 23 | 23 | 11/12 | Proven | c | Preterm + term | FCM | 3.0* | 10 | 2 | 1 | 10 |
| 16 | Elawady | 2014 [12] | Egypt | 50 | 50 | 25/25 | Proven | b | Preterm + term | FCM | 45.8 | 24 | 0 | 1 | 25 |
| 17 | Layseca-Espinosa | 2002 [8] | Mexico | 34 | 34 | 17/17 | Proven | c | Preterm + term | FCM | # | 5 | 1 | 12 | 16 |
| 18 | Ng | 2002 [9] | China | 110 | 147 | 37/110 | Proven | b | Preterm | FCM | 4000 $ | 35 | 13 | 2 | 97 |
| 19 | Soni | 2013 [28] | India | 60 | 60 | 24/36 | Proven | c | Preterm + term | FCM | 2.765* | 22 | 12 | 2 | 24 |
| 20 | Streimish(a) | 2012 [19] | USA | 649 | 997 | 3/577 | Proven | a | Preterm | FCM | 2.38 | 3 | 185 | 0 | 392 |
| 21 | Streimish(b) | 2012 [19] | USA | 47/370 | Proven | b | Preterm | FCM | 3.62 | 35 | 85 | 12 | 285 |
a, early-onset; b, late-onset; c, early & late-onset; *, CD64 index; FCM, flow cytometric technology; MFI: mean fluorescence intensity; Clinical infection defined as infection suspected on a clinical basis; proven infection defined as culture-proven infection with an identified micro-organism; #, Arithmetic mean + 3 SD of the percentage of CD64 + cells found in normal neonates; $: cAntibody-phycoerythrin molecules bound per cell